VRT752271 (BVD-523, Ulixertinib) is an orally available, highly selective, ATP-competitive, reversible ERK1/2 inhibitor with an IC50 of
VRT752271 (BVD-523, Ulixertinib) is an orally available, highly selective, ATP-competitive, reversible ERK1/2 inhibitor with an IC50 of
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin...
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin...
Ulotaront HCl is a first-in-class, orally active, CNS-active TAAR1 agonist for studies related to schizophrenia.
Ulotaront HCl is a first-in-class, orally active, CNS-active TAAR1 agonist for studies related to schizophrenia.
Ulotaront HCl is a first-in-class, orally active, CNS-active TAAR1 agonist for studies related to schizophrenia.
Ulotaront HCl is a first-in-class, orally active, CNS-active TAAR1 agonist for studies related to schizophrenia.
UM-164 is a highly potent, dual c-Src/p38inhibitor of c-Src with a binding constant Kd of 2.7 nM for c-Src and inhibits both p38α and p38β.